Drotrecogin alfa (Xigris(R)) for severe sepsis - early assessment briefs (Alert)
Swedish Council on Technology Assessment in Health Care
Record ID 32004000322
Swedish
Authors' objectives:
This review aims to assess the available evidence on drotrecogin alfa (Xigris(R)) for severe sepsis.
Authors' recommendations:
Currently there is moderate scientific evidence that show positive effects of drotrecogin alfa on survival in patients with severe sepsis. There is moderate scientific evidence of its cost effectiveness. Results from long-term follow-up on the risks and benefits of treatment have yet to be published. Therefore, it is essential to systematically monitor clinical experiences at the national level.
Authors' methods:
Review
Details
Project Status:
Completed
URL for project:
http://www.sbu.se/Published
Year Published:
2003
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Sweden
MeSH Terms
- Sepsis
Contact
Organisation Name:
Swedish Agency for Health Technology Assessment and Assessment of Social Services
Contact Address:
P.O. Box 3657, SE-103 59 Stockholm, Sweden. Tel: +46 8 4123200, Fax: +46 8 4113260
Contact Name:
registrator@sbu.se
Contact Email:
registrator@sbu.se
Copyright:
Swedish Council on Technology Assessment in Health Care (SBU)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.